Summary
58 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Analysts expect revenue to grow by 13% this fiscal year.
What to watch
- Earnings per share fell by 52% a year over the last 3 years.
- It missed profit estimates 7 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 11.4 JPY for 1 JPY of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 6.7% a year over 5 years. Over the last 3 years it fell by 3.7% a year. For the next fiscal year analysts expect revenue to grow by 13%. Earnings per share fell by 52% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 JPY of revenue goes
- Cost of sales 76 JPY
- Sales and administration 17 JPY
- Taxes and other 2.4 JPY
- Net profit 3.8 JPY
Net profit, industry median (Chemicals) 4.7 JPY
Out of every 100 JPY of revenue, 3.8 JPY is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 14.8 years of free cash flow. Its debt is larger than its cash. The debt score is high even so.
Financial health in detailDoes it pay a dividend?
Moderate, stretched- Yield
- 3.60%
- Paid out of profit
- 41%
- Raised in a row
- 2 years
You receive $0.47 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.